DNA Sciences, Bristol-Myers Enter Drug-Discovery Deal

Oct 09, 2001

NEW YORK, Oct. 9 – Beleaguered functional genomic firm DNA Sciences intends to partner with Bristol-Myers Squibb to investigate genetic variants within an undisclosed drug-discovery gene target, the companies said on Tuesday.

Terms of the deal call for DNA Sciences to use its high-throughput sequencing and genotyping facility to study Bristol-Myers’ gene in normal and affected disease populations.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

This Week in Science

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

New Framework Suggested

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

Penguins With Roving Eyes

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Funding Lost

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

Main menu